Evidence map›Paper›PMID 39182116›Full record

ArticleHarm reduction journal2024

Strategies used to reduce harms associated with fentanyl exposure among rural people who use drugs: multi-site qualitative findings from the rural opioid initiative.

Suzan M Walters, Robin Baker, David Frank, Monica Fadanelli, Abby E Rudolph, William Zule, Rob J Fredericksen, Rebecca Bolinski, Adams L Sibley, Vivian F Go and 7 more

Abstract readMulticenter Study
In one paragraph

Article in Harm reduction journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Suzan M WaltersDepartment of Population Health, New York University Grossman School of Medicine, New York, NY, USA. suzan.walters@nyulangone.org.
Robin BakerLearning Design and Innovation, Dartmouth College, Hanover, NH, USA.
David FrankDepartment of Social and Behavioral Health, School of Global Public Health, New York University, New York, NY, USA.
Monica FadanelliRollins School of Public Health, Emory University, Atlanta, GA, USA.
Abby E RudolphDepartment of Epidemiology and Biostatistics, Temple University College of Public Health, Philadelphia, PA, USA.
William ZuleRTI International, Research Triangle Park, NC, USA.
Rob J FredericksenDepartment of Medicine, University of Washington, Seattle, WA, USA.
Rebecca BolinskiSouthern Illinois University, Carbondale, IL, USA.
Adams L SibleyDepartment of Health Behavior, Gillings School of Global Public Health, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
Vivian F GoDepartment of Health Behavior, Gillings School of Global Public Health, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
Lawrence J OuelletDivision of Epidemiology and Biostatistics, School of Public Health, University of Illinois Chicago, Chicago, IL, USA.
Mai T PhoDepartment of Medicine, University of Chicago, Chicago, IL, USA.
David W SealSocial, Behavioral, and Population Sciences, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Judith FeinbergDepartments of Behavioral Medicine and Psychiatry and Medicine/Infectious Diseases, School of Medicine, West Virginia University, Morgantown, WV, USA.
Gordon SmithDepartment of Epidemiology and Biostatistics, School of Public Health, West Virginia University, Morgantown, WV, USA.
April M YoungDepartment of Epidemiology and Environmental Health, University of Kentucky College of Public Health, Lexington, KY, USA.
Thomas J StopkaDepartment of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA.

Funding

Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC)UH3DA044829 · NIDA · UNIVERSITY OF CHICAGO · PI JENKINS, WILEY, PHO, MAI TUYET · 2019 to 2022
$5.2M
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)UH3DA044798 · NIDA · UNIVERSITY OF KENTUCKY · PI COOPER, HANNAH LF, YOUNG, APRIL MARIE · 2019 to 2022
$4.4M
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)UH3DA044830 · NIDA · BAYSTATE MEDICAL CENTER, INC. · PI FRIEDMANN, PETER D, STOPKA, THOMAS J · 2019 to 2022
$3.9M
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)U24DA048538 · NIDA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., TSUI, JUDITH · 2019 to 2023
$3.7M
Community-based, client-centered prevention homes to address the rural opioid epidemicUH3DA044826 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI SEAL, DAVID W, WESTERGAARD, RYAN PATRICK · 2019 to 2022
$2.6M
Learning from the COVID-19 pandemic to improve emergency management planning for harm reduction services in rural OhioUH3DA044822 · NIDA · OHIO STATE UNIVERSITY · PI GO, VIVIAN F., MILLER, WILLIAM C · 2019 to 2022
$2.5M
Mitigating the Outcomes Associated with the Injection Drug Use Epidemic in Southern AppalachiaUH3DA044823 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZULE, WILLIAM A · 2019 to 2021
$2.4M
Kentucky Communities & Researchers Engaging to Halt the Opioid Epidemic-CARE2HOPEUG3DA044798 · NIDA · UNIVERSITY OF KENTUCKY · PI COOPER, HANNAH LF, YOUNG, APRIL MARIE · 2017 to 2018
$1.3M
Intersectional Stigma Experiences, Pre-exposure Prophylaxis (PrEP), and Other Service Use Among People Who Inject DrugsK01DA053159 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WALTERS, SUZAN M · 2021 to 2025
$927k
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) StudyUG3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2017 to 2018
$895k
NIDA NIH HHS 4UH3DA044380NIDA NIH HHS 4UH3DA044829-03NIDA NIH HHS 5UH3DA044798NIDA NIH HHS 5UH3DA044822NIDA NIH HHS 5UH3DA044826NIDA NIH HHS K01DA053159NIDA NIH HHS U24 DA048538NIDA NIH HHS U24DA048538NIDA NIH HHS UG3 DA044798NIDA NIH HHS UG3 DA044831NIDA NIH HHS UH3 DA044798NIDA NIH HHS UH3DA044823NIDA NIH HHS UH3 DA044830NIDA NIH HHS UH3DA044830
6 · The paper itself

Abstract

aimIllicitly manufactured fentanyl and its analogs are the primary drivers of opioid overdose deaths in the United States (U.S.). People who use drugs may be exposed to fentanyl or its analogs intentionally or unintentionally. This study sought to identify strategies used by rural people who use drugs to reduce harms associated with unintentional fentanyl exposure.

methodsThis analysis focused on 349 semi-structured qualitative interviews across 10 states and 58 rural counties in the U.S conducted between 2018 and 2020. Interview guides were collaboratively standardized across sites and included questions about drug use history (including drugs currently used, frequency of use, mode of administration) and questions specific to fentanyl. Deductive coding was used to code all data, then inductive coding of overdose and fentanyl codes was conducted by an interdisciplinary writing team.

resultsParticipants described being concerned that fentanyl had saturated the drug market, in both stimulant and opioid supplies. Participants utilized strategies including: (1) avoiding drugs that were perceived to contain fentanyl, (2) buying drugs from trusted sources, (3) using fentanyl test strips, 4) using small doses and non-injection routes, (5) using with other people, (6) tasting, smelling, and looking at drugs before use, and (7) carrying and using naloxone. Most people who used drugs used a combination of these strategies as there was an overwhelming fear of fatal overdose.

conclusionPeople who use drugs living in rural areas of the U.S. are aware that fentanyl is in their drug supply and use several strategies to prevent associated harms, including fatal overdose. Increasing access to harm reduction tools (e.g., fentanyl test strips, naloxone) and services (e.g., community drug checking, syringe services programs, overdose prevention centers) should be prioritized to address the polysubstance-involved overdose crisis. These efforts should target persons who use opioids and other drugs that may contain fentanyl.

Indexed as

Analgesics, OpioidFentanylHarm ReductionRural PopulationAdultDrug OverdoseFemaleHumansMaleMiddle AgedNaloxoneOpiate OverdoseOpioid-Related DisordersQualitative ResearchUnited StatesYoung AdultAnalgesics, OpioidFentanylNaloxone

Identifiers

PMID39182116
PMCPMC11344336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.